Microba Life Sciences (MAP) Q2 2025 earnings summary

Executive summary

• Q2 FY25 revenue reached AUD 4.43 million, up 102% year-over-year, with cash receipts of AUD 3.87 million, up 109% year-over-year.

• Half-year revenue totaled AUD 8.08 million, a 147% increase year-over-year, reflecting strong sales momentum.

• MetaXplore test sales in Australia rose 195% year-over-year, with over 2,560 tests sold and a 105% increase in ordering clinicians.

• UK supplement sales grew 8% year-over-year, while test sales declined 11% as the business transitions to a new growth phase; MetaXplore Early Access Program showed clinician referral rates matching Australia.

• Therapeutics pipeline advanced, with MAP315 for IBD moving to Phase 2 and immuno-oncology program sample set exceeding 5,500 patients.

Financial highlights

• Q2 FY25 group revenue: AUD 4.43 million (+102% YoY); cash receipts: AUD 3.87 million (+109% YoY).

• H1 FY25 revenue: AUD 8.08 million (+147% YoY).

• Cash balance at 31 December 2024: AUD 17.3 million.

• Personal Testing & Supplements revenue: AUD 3.5 million (+132% YoY); Research Testing revenue: AUD 0.92 million (+35% YoY).

• Net cash from operating activities in Q2 FY25 was AUD 1.8 million.

Outlook and guidance

• MetaXplore sales in Australia and UK expected to accelerate, with UK full market access targeted for H2 FY25.

• Plans to drive toward US reimbursement and expand MetaXplore to more clinicians in the UK.

• Therapeutics programs advancing, with MAP315 Phase 2 IND submission in progress and ongoing strategic partnering.

• Focus remains on executing testing and therapeutic strategies, with confidence in future growth.